USNA

$17.66

Post-MarketAs of Mar 17, 8:00 PM UTC

USANA Health Sciences, Inc.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$17.66
Potential Downside
39.6%
Whystock Fair Value$10.67
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorConsumer Defensive
IndustryPackaged Foods

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. It operates in two segments, Core nutritional and Hiya Direct-To-Consumer. Th...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$322.84M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
30.45
Beta
Defensive asset. Lower volatility than the S&P 500.
0.64
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
1.96%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.23

Recent News

Zacks
Mar 16, 2026

EHC Stock: Do Valuation and Expansion Trends Support a Hold Strategy?

EHC is expanding its inpatient rehab network and posting steady revenue and cash-flow growth, but Medicaid policy risks and higher debt remain concerns.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Mar 16, 2026

JNJ's Bladder Cancer Therapy Meets Key Goal in Early-Stage Study

J&J reports phase I study win for Erda-iDRS in NMIBC, showing strong response rates, durable control and manageable safety as mid-to-late-stage studies advance.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 13, 2026

Cigna Stock Trades Below Industry P/E: Is It Worth Holding Now?

CI trades below industry P/E as Evernorth growth, steady earnings beats and buybacks support outlook, though rising medical costs and debt remain key risks.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 13, 2026

RARE's DTX301 Meets First Key Goal in Phase III OTC Deficiency Study

Ultragenyx Pharmaceutical reports phase III success for DTX301 in OTC deficiency, lowering ammonia 18% compared to placebo and keeping levels normal through 36 weeks.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 13, 2026

2 Profitable Stocks Worth Your Attention and 1 We Brush Off

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.